Business Wire

MN-TRU-VUE

17.11.2021 08:02:11 CET | Business Wire | Press release

Share
Integral to the New MUNCH Museum’s Visitor Experience, 500+ Works Fitted With New Frames

Opened Oct. 22, 2021, the new MUNCH Museum in Oslo, Norway, displays the works of Edvard Munch (1863-1944). While Munch produced a large, complex body of work, he is most well-known for “The Scream.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116006464/en/

For the new museum, WERNER MURRER RAHMEN and HALBE Rahmen of Germany created over 500 frames to strict conservation requirements, keeping with the aesthetic of Munch’s style. Tru Vue ® Optium Museum Acrylic ® protects these world-famous artworks with an intimate viewing experience.

To watch a documentary film and learn more about MUNCH Museum’s reframing project, visit https://tru-vue.com/2021/11/new-frames-fitted-with-optium-museum-acrylic-at-munchmuseet/.

MUNCH Museum’s dual-frame system has a visible exterior and a concealed interior.

WERNER MURRER RAHMEN hand-made the outer, decorative wood framing, modeled after extensive historical research on original Munch frames. Munch used simple, wood frames and frequently left his artwork outside to directly interact with nature, resulting in a unique patina.

HALBE Rahmen engineered the vault-like, inner framing with Optium Museum Acrylic and a slim aluminum profile, which is essentially indiscernible beneath the wooden overlay. A magnetic closure allows the artwork to be front-loaded to reduce handling.

“It’s a beautiful system,” praised Barbara De Haan, MUNCH Museum’s relocation project leader. “Frames are extremely important.” Observing one of Munch’s pieces with its new frame and Optium Museum Acrylic, she commented, “It’s perfect. You see how the work comes alive. It speaks to you.”

“It was important that visitors to the new MUNCH Museum could get as close as possible to the artist’s work, to really feel and experience it; all while keeping the works protected,” said Tru Vue director of fine art and museums, Dr. Jennifer Booth. “We don’t want them to notice our product. We want them to get lost in the artwork, to see the texture of the paint, to be carried away in the emotion of the piece, rather than having that barrier.”

“With Optium Museum Acrylic, it is like you are close to the canvas with no glass in front. Glazing is necessary, but it is perfect if you don’t see it,” noted Werner Murrer.

David Halbe added, “The glazing that is in between the artwork and the visitor is very important. It should protect the painting without disturbing the view.”

Johan Øvergård, art technical manager at MUNCH, said, “The advantage of using Tru Vue Optium Museum Acrylic compared to laminated glass is the reduced weight, which eases handling, transporting and installing the artworks.” The system also allows for Munch’s artworks to be loaned internationally.

Serving museums and custom framers worldwide, Tru Vue, Inc. manufacturers UV-protective, anti-reflective, and high-performance glass and acrylic in the U.S.

“The coating process is a combination of a lot of science and a touch of art from our technical teams,” said Nate Soukup, Tru Vue vice president of operations. “We’ve worked tirelessly to perfect the production of Optium® over the last 20 years. We’ve developed the ability to produce acrylic in high volume, large sizes and with extremely tight quality specifications that our customers, like the MUNCH Museum, require.”

Link:

ClickThru

Social Media:

https://www.facebook.com/TruVueGlazing

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye